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Abstract
Background: The oncofetal protein insulin-like growth factor II mRNA binding protein 3 (IMP3) is an important factor 
for cell-migration and adhesion in malignancies. Recent studies have shown a remarkable overexpression of IMP3 in 
different human malignant neoplasms and also revealed it as an important prognostic marker in some tumor entities. 
To our knowledge, IMP3 expression has not been investigated in prostate carcinomas so far.
Methods: Immunohistochemical stainings for IMP3 were performed on tissue microarray (TMA) organized samples 
from 507 patients: 31 normal prostate tissues, 425 primary carcinomas and 51 prostate cancer metastases or castration-
resistant prostate cancers (CRPC). IMP3 immunoreactivity was semiquantitatively scored and correlated with clinical-
pathologic parameters including survival.
Results: IMP3 is significantly stronger expressed in prostate carcinomas compared to normal prostate tissues (p < 
0.0001), but did not show significant correlation with the pT-stage, the proliferation index (MIB1), preoperative serum 
PSA level and the margin status. Only a weak and slightly significant correlation was found with the Gleason score and 
IMP3 expression failed to show prognostic significance in clinico-pathological correlation-analyses.
Conclusions: Although IMP3 is overexpressed in a significant proportion of prostate cancer cases, which might be of 
importance for novel therapeutic approaches, it does not appear to possess any immediate diagnostic or prognostic 
value, limiting its potential as a tissue biomarker for prostate cancer. These results might be corroborated by the fact, 
that two independent tumor cohorts were separately reviewed.
Background
Insulin-like growth factor II mRNA binding protein 3
(IMP3), an oncofetal protein and member of the insulin-
like growth factor II mRNA binding protein family, has
recently raised attention since it appears to play an
important role in cell-migration and adhesion in various
malignant neoplasms [1]. It functions in RNA shuttling
and translational control: to date three members of this
family are known: IMP1, IMP2 and IMP3 [2,3]. The
human IMP3 gene is located at chromosome 7p15 with
an identical sequence to that of KOC (KH domain con-
taining protein overexpressed in cancer) and shows an
overall sequence identitiy of 59% with other mRNA bind-
ing family members [4].
Physiologically, IMP3 is commonly expressed during
embryogenesis in mouse and human organs, but rarely in
adult tissue [5]. Current studies reveal a remarkable re-
expression of IMP3 in different human malignancies, e.g.
in ovarian cancer, non-small cell lung cancer, malignant
melanoma, osteosarcoma, pancreatic ductal adenocarci-
noma, melanoma, metastatic melanoma, colorectal ade-
nocarcinoma, urothelial tumors, extrapulmonary small
cell carcinoma, endometrial carcinoma, malignant follic-
ular pattern thyroid lesions, invasive mammary
carcinoma, esophageal adenocarcinoma, adenocarci-
noma on endoscopic bile duct biopsy/bile duct carci-* Correspondence: glen.kristiansen@usz.ch
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Page 2 of 6noma and in high-grade dysplasia in the extrahepatic
biliary tract [6-23].
As the most common malignant neoplasm in men,
prostate cancer is the second most common cause of
tumor related deaths in the United States [24]. Although
prostate cancer is commonly a slowly progressing disease
that might not become clinically apparent during the
patient's lifetime, a certain proportion of cases does take
a more serious course associated with a poor clinical out-
come [25]. Conventional prognostic factors such as Glea-
son score, preoperative PSA levels or ratio of involved
biopsies only insufficiently predict patient outcome for
currently available therapies. They are even more limited
in identifying insignificant prostate cancer, i.e. cancer
that might be left untreated without shortening the
patients life expectancy but sparing him the morbidity of
unwarranted treatment. Therefore, further efforts to find
new diagnostic pathways and therapeutic options are
urgently demanded to optimise patient management [26].
In this study we analysed by immunohistochemistry the
protein expression profile of IMP3 in benign prostate tis-
sue, primary prostate cancer, castration resistant prostate
cancer (CRPC) and prostate cancer metastases and corre-
lated IMP3 expression to clinico-pathological parameters
including biochemical recurrence times.
Methods
Patients
Tissue samples from 507 patients were enclosed in this
study: 83.8% (n = 425) primary carcinoma following radi-
cal prostatectomy in the department of Urology of the
University Hospital of Zurich (USZ) and the department
of Urology of the University Hospital of Regensburg,
10.1% (n = 51) prostate cancer metastases or castration-
resistant prostate cancer (CRPC) and 6.1% (n = 31) non-
malignant/normal prostate tissue. For Zurich, the median
follow up time of the patients was 95 months (0 to 167
months), median age 66 (46 to 95 years). For Regensburg,
the median follow up time of the patients was 63 months
(0 to 111 months), median age 63 (47 to 76 years). None
of the patients received hormonal therapy or chemother-
apy prior to surgery.
Tissue Microarray (TMA)
For the construction of the tissue microarray (TMA)
fomalin fixed and paraffin embedded tissue was used as
described previously [27]. Briefly, from tissue sample
from each patient one core of 0.6 mm diameter was
punched out from the donor block and transfered to the
recipient (TMA) block. Each tumor was represented by a
single but representative core. To exclude the potential
influence of molecular field effects, normal tissue was
sampled from transurethral resections of patients with
benign hyperplasia of the prostate and unremarkable PSA
levels.
Immunohistochemistry/Evaluation of the staining pattern
For immunohistochemical staining freshly cut 3 μm thick
sections of the TMA block were mounted on superfrost
slides (Menzel Gläser, Braunschweig, Germany). For
IMP3 detection, staining were performed on a BondMax
automated staining system (Vision BioSystems Ltd., New-
castle upon Tyne, United Kingdom) with a monoclonal
mouse antibody (clone 69.1, dilution 1:100, DAKO,
Glostrup, Denmark). After epitope retrieval (H2-Buffer,
Vision BioSystems Ltd., Newcastle upon Tyne, United
Kingdom) primary antibody was detected by Refine DAB
method (Vision BioSystems Ltd., Newcastle upon Tyne,
United Kingdom). Slides were counterstained with hema-
toxylin prior to dehydration and coverslipping.
Since IMP3 protein is relatively homogeneous
expressed on prostate cancer, staining intensity (exclu-
sively cytoplasmatic staining pattern was evaluated) was
assigned to a semiquantitive, four-tired score. In cases
with heterogeneity, the predominant staining intensity (>
80%) was counted: (0) negative, + (1) weak, ++ (2) moder-
ate, +++ (3) strong. Evaluation was done by KI, GK, UZ
and FF simultaneously at a multiheaded microscope.
Statistics
Statistical analyses were performed with SPSS, Version
17, according to Spearman and with Linear-by-linear
association to compare the IMP3 expression pattern with
clinico-pathologic parameters. Analysis of biochemical
recurrence times was performed according to Kaplan
Meier with log rank test.
Results
Expression of the IMP3 protein in prostate tissues
In samples from non neoplastic prostate tissue and from
benign prostate hyperplasia, no remarkable IMP3 protein
expression was found (n = 31, 100% negative).
The primary prostate carcinomas (n = 425) 16.7% (n =
71) showed no IMP3 expression, 69.2% (n = 294) did
show weak staining, 13.4% (n = 57) moderate and 0.7% (n
= 3) strong staining for IMP3 (median = 1; Figure 1).
51 samples from lymphnode-and organ metastases as
well as from cases with castration-resistant prostate can-
cer disease were analysed: 25.5% (n = 13) showed no
IMP3 expression, 58.8% (n = 30) a weak expression, 5.9%
(n = 3) moderate and 9.8% (n = 5) strong IMP3 expression
level (median = 1).
The difference of IMP3 immunoreactivity between nor-
mal and tumor tissues was highly significant (p < 0.001).
Correlation of IMP3 expression with clinico-pathological 
factors
In a nonparametric Spearman rank correlation analysis,
the expression of IMP3 did show a minor, but weak sig-
nificant correlation with the Gleason score (correlation
coefficient (CC) = 0.1, p = 0.04). No significant associa-
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0.412), the proliferation index (MIB1) (CC = 0.060, p =
0.377), preoperative serum PSA level (CC = 0.061, p =
0.213) and the margin status (R0 vs. R1) (CC = 0.089, p =
0.068). Additional cross table analysis validated these
results (Table 1).
Survival analysis
In an univariate Cox-analysis for primary carcinomas,
Gleason-score (5-6 vs. 7 vs. 8-9), pT-status (pT2 vs. pT3/
4), pre OP PSA (< 10 ng/ml vs. ≥10 ng/ml) and margin-
status (R0 vs. R1) were confirmed as significant prognos-
tic factors for PSA free survival times whereas patients
age (≤64y vs. > 64y) and IMP3 expression (0/1/2/3) were
not significant factors (Table 2). Also, in a Kaplan-Meier
survival analysis there was a non significant prognostic
value for IMP3 expression (negative vs. positive) (p =
0.343), although IMP3 positive cases showed a slightly
more unfavourable course (Figure 2). If analysed sepa-
rately, in both cohorts from Zurich (USZ) and Regens-
burg IMP3 expression was not a significant factor: Zurich
RR (Exp(B)) = 1.444, p-Value = 0.102; Regensburg RR
(Exp(B)) = 1.022, p-Value = 0.932.
Discussion
An accurate and early diagnosis is essential for efficient
management of prostate cancer [24,25]. Therefore, to
complement improvements in the clinical management,
substantial progress in the diagnostic pathway of prostate
cancer is urgently needed [26].
The oncofetal protein IMP3 plays an important role in
translational control of Insulin-like Growth Factor II
leader-3 mRNA during proliferation and in cell-adhesion
[1,3,28] and it regulates, among others, CD24 and
Figure 1 IMP3 expression in benign prostate tissue and prostate carcinoma. (A) No or weak IMP3 expression in benign prostate tissue; (B-D) IMP3 
expression in primary prostate carcinoma: (B) weak, (C) moderate and (D) strong expression.
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markers for prostate cancer in earlier studies [1,29].
Therefore we had expected a prognostic value of IMP3 in
prostate cancer, as has already been shown in other
malignancies [6-23]. In addition, a first phase I clinical
trial with an anti-IMP3 immunotherapy in non-small cell
lung cancer showed a high level of safety and so poten-
tially offers a new therapeutic option for other malignan-
cies as well [30]. This demonstrates that IMP3 has not
only a high diagnostic potential, but is also a very promis-
ing target for therapy, suggesting further studies into this
member of the insulin-like growth factor II mRNA bind-
ing protein family are warranted.
Our results show, that IMP3 is only rarely expressed in
benign prostate tissue whereas it shows a significantly but
only slightly higher expression level in malignant prostate
tissue. The diagnostic use of IMP3 in difficult or doubtful
lesions found at biopsy cannot be recommended, since
most cases show only a weak IMP expression, which can -
in a diagnostic real life situation - be troublesome to dif-
ferentiate from background. Only approximately 14.1% (n
= 60) of cases showed moderate to strong IMP3 expres-
sion, a rate too low to recommend the use of IMP3 as a
diagnostic marker of malignancy. Although higher rates
of IMP3 expression where seen in cases with higher Glea-
son scores, higher pre-OP PSA level and higher prolifera-
tive fractions, still no significant prognostic relevance for
IMP3 could be demonstrated (Table 2). The IMP3 expres-
sion (negative vs. positive) in a Kaplan-Meier survival
analysis appears to possess a minor prognostic value at
Table 1: IMP3 related to clinico-pathological parameters of prostate cancer
Variable Patients (n) Number of patients
 (IMP-Expression) (%)
p-Value 
(linear by linear)
0 1 2 3
pT-status 0.5
pT2 213 46 (21.6%) 131 (61.5%) 34 (16%) 2 (0.9%)
pT3&4 212 25 (11.8%) 163 (76.9%) 23 (10.8%) 1 (0.5%)
Gleason score 0.048
5-6 129 29 (22.5%) 85 (65.9%) 14 (10.9%) 1 (0.8%)
7 182 28 (15.4%) 127 (69.8%) 26 (14.3%) 1 (0.5%)
8-9 114 14 (12.3%) 82 (71.9%) 17 (14.9%) 1 (0.9%)
Margin status 0.115
R0 262 54 (20.6%) 171 (65.3%) 34 (13%) 3 (1.1%)
R1 163 17 (10.4%) 123 (75.5%) 23 (14.1%) 0 (0%)
PSA (pre-OP) 0.21
< 10 ng/ml 192 37 (19.3%) 130 (67.7%) 24 (12.5%) 1 (0.5%)
≥10 ng/ml 233 34 (14.6%) 164 (70.4%) 33 (14.2%) 2 (0.9%)
Age 0.693
≤64 y 230 33 (14.3%) 168 (73%) 27 (11.7%) 2 (0.9%)
> 64 y 195 38 (19.5%) 126 (64.6%) 30 (15.4%) 1 (0.5%)
Distribution of IMP3 expression in primary prostate cancer according to clinico-pathological parameters
Table 2: Univariate Cox analysis of PSA recurrence free survival times
Parameter RR (Exp (B)) p-Value
Gleason-Score 5-6/7/8-9 1.713 < 0.001
pT-status pT2/pT3&4 2.387 < 0.001
pre OP PSA < 10 ng/ml/≥10 ng/ml 1.95 0.003
Age ≤64y/> 64y 1.169 0.449
Margin status R0/R1 2.204 < 0.001
IMP3 0/1/2/3 1.181 0.332
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can at best be interpreted as a very loose trend. One
might argue that this lack of prognostic significance we
found could be an idiosyncrasy of this tumor cohort. In
this study two different patient/tumor cohorts were anal-
ysed, so it is unlikely, that a larger cohort with even longer
follow up times would demonstrate a prognostic value of
IMP3. We cannot exclude a possible minor prognostic
value of IMP3, but on the basis of our data we assume
that IMP3 is very unlikely to represent a strong prognos-
tic biomarker in prostate cancer.
Conclusions
Although IMP3 is overexpressed in prostate cancer, pref-
erentially of higher Gleason scores, it does not have the
same outstanding diagnostic and prognostic value for
prostate cancer, as it has for other malignancies.
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